Sodium glucose cotransporter 2 (SGLT2) inhibitors improve islet function in patients with type 2 diabetes by reducing plasma ketone body levels

tianpei Hong

Open source

DOI
10.25934/pr00010954
Published
2025
Container
Not recorded
Publisher
Vivli
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.25934/pr00010954,
  title = {Sodium glucose cotransporter 2 (SGLT2) inhibitors improve islet function in patients with type 2 diabetes by reducing plasma ketone body levels},
  author = {tianpei Hong},
  year = {2025},
  doi = {10.25934/pr00010954},
  url = {https://doi.org/10.25934/pr00010954}
}

RIS

TY  - JOUR
TI  - Sodium glucose cotransporter 2 (SGLT2) inhibitors improve islet function in patients with type 2 diabetes by reducing plasma ketone body levels
AU  - tianpei Hong
PY  - 2025
DO  - 10.25934/pr00010954
UR  - https://doi.org/10.25934/pr00010954
ER  - 

APA

Hong, T. (2025). Sodium glucose cotransporter 2 (SGLT2) inhibitors improve islet function in patients with type 2 diabetes by reducing plasma ketone body levels. https://doi.org/10.25934/pr00010954

Source records